All In Biotech

Drug Trial Radar · NCT01103635

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

A Phase 1 Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Feb 2010

Primary completion

May 2016

Study completion May 2, 2016

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tremelimumab together with CD 40 agonist monoclonal antibody CP-870, 893 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving tremelimumab together with CD40 agonist monoclonal antibody CP-870,893 in treating patients with metastatic melanoma.

Conditions

  • Recurrent Melanoma
  • Stage IV Melanoma

Interventions

  • CD40 agonist monoclonal antibody CP-870,893Biological

    Given IV

  • tremelimumabBiological

    Given IV

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Toxicity as assessed by CTCAE v3.0Time frame: 2 years
  2. ResponseTime frame: 2 years
  3. Immunological outcomes (analysis of antigen presenting cell activation, antigen-specific T cells, and tumor-specific T cells)Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abramson Cancer Center of The University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.